title: A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation.
abstract: Atrial fibrillation (AF) is a common cardiac arrhythmia. Dabigatran etixalate (DE) is one of the new oral anticoagulant drugs being used in nonvalvular AF (NVAF). There is no adequate real world data in different populations about DE. The aim of this registry was to evaluate the efficacy and safety of DE Consecutive NVAF patients treated with warfarin or both DE doses were enrolled during 18 months study period. The patients were re-evaluated at regular 6-month intervals during the follow-up period. During the follow-up period outcomes were documented according to RELY methodology A total of 555 patients were analyzed. There was no significant difference in ischemic stroke rates (p = 0.73), death rates (p = 0.15) and MI rates (p = 0.56) between groups. The rate of major bleeding was significantly higher in warfarin and dabigatran 150 mg group than dabigatran 110 mg (p < 0.001). Intracranial bleeding rate and relative risk were significantly lower in dabigatran 110 mg group than warfarin group (p = 0.004). Dyspepsia was significantly higher in both DE doses than warfarin (p = 0.004) Both DE doses are as effective as warfarin in reducing stroke rates in NVAF patients, without increasing MI rates. Intracranial bleeding rates are significantly lower in warfarin than both doses of DE and gastrointestinal bleeding risk increases with increased DE doses.
authors.affiliation: Department of Cardiology, Medical Park Ankara Hospital, Ankara, Turkey. byavuzmd@gmail.com.
authors.forename: Bunyamin
authors.initials: B
authors.lastname: Yavuz
authors.affiliation: Department of Cardiology, Kecioren Teaching and Research Hospital, Ankara, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ayturk
authors.affiliation: Department of Cardiology, 29 Mayıs Hospital, Ankara, Turkey.
authors.forename: Selcuk
authors.initials: S
authors.lastname: Ozkan
authors.affiliation: Department of Cardiology, Kecioren Teaching and Research Hospital, Ankara, Turkey.
authors.forename: Mujgan
authors.initials: M
authors.lastname: Ozturk
authors.affiliation: Department of Cardiology, Karsiyaka State Hospital, Ankara, Turkey.
authors.forename: Caner
authors.initials: C
authors.lastname: Topaloglu
authors.affiliation: Department of Cardiology, Memorial Ankara Hospital, Ankara, Turkey.
authors.forename: Hakan
authors.initials: H
authors.lastname: Aksoy
authors.affiliation: Department of Cardiology, Kirikkale State Hospital, Ankara, Turkey.
authors.forename: Cengiz
authors.initials: C
authors.lastname: Şabanoglu
authors.affiliation: Department of Cardiology, Medical Park Ankara Hospital, Ankara, Turkey.
authors.forename: Ali Cevat
authors.initials: AC
authors.lastname: Tanalp
authors.affiliation: Department of Medicine, Kecioren Teaching and Research Hospital, Ankara, Turkey.
authors.forename: Kursat
authors.initials: K
authors.lastname: Dal
authors.affiliation: Department of Medicine, 29 Mayıs Hospital, Ankara, Turkey.
authors.forename: Naim
authors.initials: N
authors.lastname: Ata
authors.affiliation: Division of Geriatric Medicine, Department of Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
authors.forename: Burcu Balam
authors.initials: BB
authors.lastname: Yavuz
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D000069604:Dabigatran / Q000008:administration & dosage / Q000494:pharmacology*; D004415:Dyspepsia; D005260:Female; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced; D008297:Male; D009203:Myocardial Infarction; D012042:Registries; D020521:Stroke / Q000517:prevention & control; D014859:Warfarin / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D000069604:Dabigatran
keywords: Atrial fibrillation; Dabigatran; NOAC; Real world data